NCT01925196 |
|
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
View
|
NCT06467175 |
|
The Benefits of Long-read High-throughput Genomic Sequencing for the Causal Diagnosis of Cerebellar Ataxias
|
View
|
NCT06083584 |
|
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis
|
View
|
NCT03293069 |
|
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
|
View
|
NCT05053035 |
|
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
|
View
|
NCT01459302 |
|
Genetic Study of Familial and Sporadic ALSMotor Neuron Disease Miyoshi Myopathy and Other Neuromuscular Disorders
|
View
|
NCT04931862 |
|
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis ALS or Frontotemporal Dementia FTD
|
View
|
NCT05358431 |
|
Stratification of Presymptomatic Amyotrophic Lateral Sclerosis the Development of Novel Imaging Biomarkers
|
View
|
NCT04060082 |
|
Voices Of Individuals Challenges and Experiences Of bvFTD
|
View
|
NCT02372773 |
|
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
|
View
|
NCT04220021 |
|
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALSFTD
|
View
|
NCT03573466 |
|
Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS
|
View
|
NCT02686268 |
|
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
|
View
|
NCT05747937 |
|
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
|
View
|
NCT04288856 |
|
Study to Assess the Safety Tolerability Pharmacokinetics and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis ALS
|
View
|
NCT03626012 |
|
A Study to Assess the Safety Tolerability and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
|
View
|
NCT03865420 |
|
Amyotrophic Lateral Sclerosis ALS Families Project
|
View
|
NCT03987295 |
|
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia FTD Patients INFRONT-2
|
View
|
NCT05683860 |
|
Open-label Extension OLE Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis ALS andor Frontotemporal Dementia FTD
|
View
|
NCT04516499 |
|
Neurofilament Surveillance Project NSP
|
View
|
NCT04639622 |
|
GENetic Fronto Temporal Dementia Initiative in Lille
|
View
|
NCT05852405 |
|
Clinical Characteristics Natural History Health Care Measures and Genetic Screening in Patients With ALS
|
View
|
NCT04819555 |
|
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS
|
View
|
NCT04993755 |
|
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALSFTD
|
View
|
NCT05163886 |
|
Study of Safety Tolerability and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
|
View
|
NCT05189106 |
|
Neurodegenerative Alzheimers Disease and Amyotrophic Lateral Sclerosis NADALS Basket Trial
|
View
|
NCT05483322 |
|
An Open-Label Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia FTD
|
View
|
NCT05779813 |
|
Genetic Frontotemporal Dementia Initiative for Neurodevelopment
|
View
|
NCT00317616 |
|
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis Pre-fALS Study
|
View
|
NCT02590276 |
|
Predict to Prevent Frontotemporal Lobar Degeneration FDT and Amyotrophic Lateral Sclerosis ALS
|
View
|